Detalle Publicación

ARTÍCULO

Radium-223 international early access program: results from the Spanish subset

Autores: Carles, J. (Autor de correspondencia); Mendez, M. J.; Pinto, A.; Saez, M. I.; Arranz, J. A.; Maroto, P.; Lopez-Criado, P.; Mellado, B.; Donas, J. G.; Hernando, S.; Leon, L.; del Alba, A. G.; Lainez, N.; Esteban, E.; Reynes, G.; Pérez Gracia, José Luis; Germa, J. R.; Lopez-Brea, M.; Perez-Valderrama, B.; Moretones, C.; Castellano, D.
Título de la revista: FUTURE ONCOLOGY
ISSN: 1479-6694
Volumen: 14
Número: 1
Páginas: 41 - 50
Fecha de publicación: 2018
Resumen:
Aim: To report results from the Spanish subset included in the radium-223 international early access program (iEAP). Patients & methods: Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles. Results: The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with >= 50% confirmed declines in prostate-specific antigen was 9%. The median overall survival was 14 months. Grade 3 or 4 treatment emergent adverse events (TEAEs) occurred in 34% of patients (serious TEAEs 28%, TEAEs leading to discontinuation 27%). Conclusion: Outcomes of the Spanish subset are consistent with the iEAP. Radium-223 was generally well tolerated with no safety concerns.
DOI: https://doi.org/10.2217/fon-2017-0297
Impacto:
Google Scholar